DOT1L and leukemia: The DOT1L inhibitor Pinometostat (EPZ5767) used in this study recently completed a phase I clinical trial for adult leukemia (NCT01684150) and was shown to have modest activity as a single agent, but was generally safe and, therefore, potentially suitable for combinatory approaches with other chemotherapeutic agents [28].